Vistagen Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 13, 2025
VTGN$0.18-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months EndedDecember 31, | |||||
|---|---|---|---|---|---|
| 2024 · 2023 | |||||
| Cash flows from operating activities: | |||||
| Net loss | $(37,783) | $(19,841) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | 110 | 94 | |||
| Stock-based compensation | 3,352 | 1,660 | |||
| Amortization of operating lease right-of-use asset | 359 | 327 | |||
| Accretion on marketable securities | (261) | - | |||
| Changes in operating assets and liabilities: | |||||
| Prepaid expenses and other current assets | 125 | 202 | |||
| Other assets | 190 | (212) | |||
| Operating lease liability | (407) | (359) | |||
| Deferred sublicense and other revenue, net of deferred contract acquisition costs | (446) | 695 | |||
| Accounts payable and accrued expenses | 2,726 | (1,394) | |||
| Net cash used in operating activities | (32,035) | (18,828) | |||
| Cash flows from investing activities: | |||||
| Purchases of laboratory and other equipment | (103) | (32) | |||
| Sales and maturities of marketable securities | 7,497 | - | |||
| Purchases of marketable securities | (21,069) | - | |||
| Net cash used in investing activities | (13,675) | (32) | |||
| Cash flows from financing activities: | |||||
| Proceeds from issuance of common stock and warrants, net of issuance costs | - | 93,517 | |||
| Net proceeds from sale of common stock under Open Market Sale Agreement, net of offering costs | 1,058 | 36,243 | |||
| Net proceeds from sale of common stock under 2019 Employee Stock Purchase Plan | 201 | 7 | |||
| Repayment of notes payable | - | (985) | |||
| Net cash provided by financing activities | 1,259 | 128,782 | |||
| Net increase (decrease) in cash and cash equivalents | (44,451) | 109,922 | |||
| Cash and cash equivalents at beginning of period | 119,166 | 16,638 | |||
| Cash and cash equivalents at end of period | $74,715 | $126,560 | |||
| Supplemental disclosure of noncash activities: | |||||
| Non-cash investing and financing activities: | |||||
| Insurance premiums settled by issuing note payable | $ | - | $880 | ||
| Purchases of equipment included in accounts payable | $ | - | $18 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.